- Home
- PRKS vs DNLI Comparison
PRKS vs DNLI Comparison
Compare PRKS & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRKS
- DNLI
- Stock Information
- Founded
- PRKS 1959
- DNLI 2013
- Country
- PRKS United States
- DNLI United States
- Employees
- PRKS N/A
- DNLI N/A
- Industry
- PRKS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRKS Health Care
- DNLI Health Care
- Exchange
- PRKS Nasdaq
- DNLI Nasdaq
- Market Cap
- PRKS 3.2B
- DNLI 3.3B
- IPO Year
- PRKS 2013
- DNLI 2017
- Fundamental
- Price
- PRKS $52.83
- DNLI $22.99
- Analyst Decision
- PRKS Buy
- DNLI Strong Buy
- Analyst Count
- PRKS 9
- DNLI 13
- Target Price
- PRKS $61.78
- DNLI $38.00
- AVG Volume (30 Days)
- PRKS 893.4K
- DNLI 1.1M
- Earning Date
- PRKS 02-28-2025
- DNLI 02-25-2025
- Dividend Yield
- PRKS N/A
- DNLI N/A
- EPS Growth
- PRKS 2.23
- DNLI N/A
- EPS
- PRKS 3.84
- DNLI N/A
- Revenue
- PRKS $1,729,882,000.00
- DNLI N/A
- Revenue This Year
- PRKS $1.59
- DNLI N/A
- Revenue Next Year
- PRKS $1.43
- DNLI $651.24
- P/E Ratio
- PRKS $13.77
- DNLI N/A
- Revenue Growth
- PRKS 0.10
- DNLI 204.74
- 52 Week Low
- PRKS $44.72
- DNLI $14.56
- 52 Week High
- PRKS $60.83
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- PRKS 44.44
- DNLI 53.06
- Support Level
- PRKS $51.03
- DNLI $21.55
- Resistance Level
- PRKS $54.36
- DNLI $24.29
- Average True Range (ATR)
- PRKS 1.82
- DNLI 1.22
- MACD
- PRKS 0.07
- DNLI 0.17
- Stochastic Oscillator
- PRKS 33.99
- DNLI 73.14
About PRKS United Parks & Resorts Inc. Common Stock
United Parks & Resorts Inc operates in the United States leisure industry. Its core business is the operation of theme parks and such entertainment facilities involving sea animals across the country under prominent brands such as SeaWorld, Busch Gardens, Aquatica, Discovery Cove and Sesame Place. The company generates majority of its revenue from selling admission tickets for its theme parks.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.